Stand & Move at Work

Obesity Clinical Trial

Official title:

Stand & Move at Work: A Group Randomized Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02566317
• Other study ID #: R01CA198971
• Status: Completed
• Phase: N/A
• Start date: January 15, 2016
• Est. completion date: December 15, 2018

Study information

• Verified date: October 2019
• Source: Arizona State University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A trial testing the efficacy of sit-stand workstations on decreasing sitting time and increasing light-intensity physical activity in samples of office worksites.

Description:

With traditional approaches to increasing MVPA (moderate to vigorous physical activity) in the workplace being unsustainable due to the requirement of deliberate and dedicated time away from work, this group-randomized trial will test the efficacy of sit-stand workstations on decreasing sitting time and increasing light-intensity physical activity (LPA) in a highly generalizable sample of office worksites using a multi-level intervention with high potential for dissemination.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 630
• Est. completion date: December 15, 2018
• Est. primary completion date: December 15, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Worksite-level inclusion criteria:

• Size: Small to moderate size worksite (20-60 employees)

• Schedule: >80% of employees full time

• Occupation: Seated office work, primarily computer- and- telephone-based work, little movement or walking

• Wellness environment: Not currently undergoing a wellness program aimed at increasing activity at work

• Workstations: Willing to have sit-stand workstations installed at a worksite

• Willing to be randomized: Willing to be randomized to either intervention conditions

Member-level inclusion criteria:

• Age: 18 years and older

• Health status: Generally good health and able to safely increase LPA and reduce sitting time

• Employment status: Any sedentary job, sitting most of the say, little standing or walking

• Occupation: Traditional sitting desk, willing to have a sit-stand workstation installed at desk

• Workstation: traditional sitting desk;willing to have a sit-stand workstation installed at desk

Exclusion Criteria:

• contraindication to prolonged standing at work

Related Conditions & MeSH terms

• Diabetes
• Hypertension
• Obesity

Intervention

Device:
• Sit-Stand workstation
Installation of a sit-stand desk at work

Behavioral:
• Move
A multi-level individual, social, environmental, and organizational intervention targeting increases in light-intensity physical activity in the workplace

Locations

Country	Name	City	State
United States	University of Minnesota	Minneapolis	Minnesota
United States	Arizona State University	Tempe	Arizona

Sponsors (2)

Lead Sponsor	Collaborator
Arizona State University	University of Minnesota - Clinical and Translational Science Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Sleep Substudy	24h wrist accelerometry in individuals with minor-moderate sleep complaints	1 year
Other	Ambulatory Blood Pressure	Dynamic changes in ambulatory blood pressure in prehypertensives	3 months
Other	Ecological Momentary Assessment of Mood	Periodic monitoring of mood, energy, fatigue in smartphone users	1 year
Other	Dynamic Glucose Control	Continuous glucose monitoring in prediabetics	3 months
Primary	Mean Change in Light-intensity Physical Activity at Work From Baseline to 12 Months	Measured via 7d of activPAL accelerometry (value at 12 months minus value at baseline)	1 year
Primary	Mean Change in Sitting Time at Work From Baseline to 12 Months	Measured via 7d of activPAL accelerometry (value at 12 months minus value at baseline)	1 year
Secondary	Clustered Metabolic Risk Score From Baseline to 12 Months	Clustered metabolic risk score (fasting glucose, insulin, triglycerides, HDL-cholesterol, blood pressure); value at 12 months minus value at baseline; higher scores indicate better outcome. The Z-score for each component (fasting glucose, insulin, triglycerides, HDL-cholesterol, blood pressure) based on the baseline mean and standard deviation of the entire group was computed and summed for each participant (HDL z-score was subtracted rather than added). The sum of these z-scores represents the metabolic risk score.	1 year